Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2019-10-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT04692675
The Active Surveillance Study
NCT05810467
Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer
NCT03979573
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
NCT01464216
Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance
NCT02971085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient must understand the sense of research, agree to participate and sign a form of agreement
* low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA\<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
* not more than 33% cores with adenocarcinoma
Exclusion Criteria
* other prostatic malignant neoplasms
* other oncological diseases
* treatment with 5-alfa-reductase inhibitors
* patient's refuse to continue study
* patient's desire to begin treatment
50 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Moscow Regional Research and Clinical Institute (MONIKI)
OTHER_GOV
Pirogov Russian National Research Medical University
OTHER
I.M. Sechenov First Moscow State Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dmitry Enikeev, MD, PhD
Deputy director for Research, Institute for Urology and Reproductive Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Urology and Reproductive Health, Sechenov University.
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sechenov-AS-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.